LONDON, January 27, 2025 – Leading international law firm Proskauer today announced that it advised Rivean Capital on the formation and closing of its continuation fund Rivean Special Opportunity Fund II.
Rivean Special Opportunity Fund II provides additional capital to support Rivean Capital on its acquisition, alongside PSG Equity, of Corilus N.V. ("Corilus"), a leader in medical software solutions for the primary care market in Belgium. The transaction includes new investment from PSG Equity and re-investment from Rivean Capital, following its initial investment in Corilus in 2020.
Rivean Capital successfully raised the continuation fund, which closed at its hard cap in a single closing, with capital from a broad range of existing and new investors. The fund also includes substantial additional capital to further support Corilus' organic growth plan and acquisition pipeline.
The Proskauer team advising Rivean Capital was led by partners Nigel van Zyl, Nick Rose and Warren Allan. It also included associates Lucy Spencer, Giulia Brunello, Lidia Grasu and Alexander Thompson (Private Funds). The team also included partners Mary Kuusisto and Frazer Money and associates April McLeod, Emma McDonnell and Benjamin Swiszcz (Tax); partners Robert Sutton and John Verwey, special regulatory counsel Rachel Lowe and associates Sasha Burger and Michael Singh (Regulatory); partner Mary Wilks (Antitrust); partner Cameron Roper (Fund Finance) and partner Adam Scoll (ERISA).